
Syneos Health SYNH
Quarterly report 2023-Q1
added 05-10-2023
Syneos Health ROCE Ratio 2011-2026 | SYNH
Annual ROCE Ratio Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.41 | 4.52 | 5.75 | 4.8 | 2.58 | 20.94 | 21.68 | 10.98 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.68 | 2.58 | 10.33 |
Quarterly ROCE Ratio Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 | 4.48 | 7.89 | 9.07 | 11.65 | 7.88 | 10.93 | 10.56 | 9.06 | 5.63 | 8.39 | 7.63 | 8.47 | 7.85 | 7.88 | 6.98 | 6.14 | 5.61 | 3.32 | -1.01 | -1.75 | -0.96 | 13.08 | 29.09 | 41.9 | 51.53 | 55.26 | 62.58 | 65.96 | 70.07 | 56.52 | 41.93 | 27.4 | 16.23 | 15.61 | 9.81 | 7.8 | 4.08 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.07 | -1.75 | 18.57 |
ROCE Ratio of other stocks in the Diagnostics research industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-89.9 | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
25.0 | $ 115.18 | -0.26 % | $ 35 B | ||
|
Aspira Women's Health
AWH
|
114.15 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-360.98 | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
1809.55 | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-2.26 | - | - | $ 562 M | ||
|
Akumin
AKU
|
58.25 | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
-41.81 | $ 16.21 | 0.06 % | $ 175 M | ||
|
Accelerate Diagnostics
AXDX
|
62.7 | - | -61.36 % | $ 2.46 M | ||
|
IQVIA Holdings
IQV
|
33.55 | $ 170.71 | -1.47 % | $ 29.3 B | ||
|
Global Cord Blood Corporation
CO
|
12.48 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-18.87 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-347.69 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-15.41 | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-8.59 | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
9.75 | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
-181.44 | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
-10.16 | $ 17.85 | -2.51 % | $ 951 M | ||
|
Biodesix
BDSX
|
-41.6 | $ 15.52 | 2.95 % | $ 2.01 B | ||
|
Enzo Biochem
ENZ
|
-22.04 | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
-4.81 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-219.45 | - | -20.0 % | $ 1.06 M | ||
|
QIAGEN N.V.
QGEN
|
8.07 | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
-77.18 | $ 2.61 | 2.35 % | $ 84.7 K | ||
|
Biomerica
BMRA
|
-125.14 | $ 2.16 | -0.46 % | $ 4.96 M | ||
|
BioNano Genomics
BNGO
|
-75.05 | $ 1.17 | -2.92 % | $ 6.37 M | ||
|
Co-Diagnostics
CODX
|
-236.6 | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
0.8 | $ 167.37 | -3.75 % | $ 8.3 B | ||
|
Castle Biosciences
CSTL
|
1.9 | $ 24.86 | 0.08 % | $ 691 M | ||
|
Danaher Corporation
DHR
|
8.93 | $ 192.01 | 0.47 % | $ 137 B | ||
|
Celcuity
CELC
|
-171.24 | $ 113.96 | 1.18 % | $ 5.33 B | ||
|
DexCom
DXCM
|
33.2 | $ 62.95 | 1.17 % | $ 24.6 B | ||
|
Fulgent Genetics
FLGT
|
-6.52 | $ 16.5 | -1.93 % | $ 499 M | ||
|
Chembio Diagnostics
CEMI
|
-132.81 | - | 0.22 % | $ 16.8 M | ||
|
Guardant Health
GH
|
440.3 | $ 89.89 | -4.2 % | $ 11.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
21.7 | $ 198.66 | 0.76 % | $ 22.1 B | ||
|
Motus GI Holdings
MOTS
|
-443.13 | - | -34.28 % | $ 263 K | ||
|
ICON Public Limited Company
ICLR
|
4.69 | $ 109.23 | -4.34 % | $ 9.01 B | ||
|
Illumina
ILMN
|
-35.1 | $ 127.74 | 0.28 % | $ 20.3 B | ||
|
Interpace Biosciences
IDXG
|
18.26 | $ 1.97 | 0.63 % | $ 8.72 M | ||
|
Laboratory Corporation of America Holdings
LH
|
16.06 | $ 274.86 | 0.42 % | $ 22.9 B | ||
|
Lantheus Holdings
LNTH
|
28.52 | $ 76.46 | 0.47 % | $ 5.16 B | ||
|
Medpace Holdings
MEDP
|
116.53 | $ 495.18 | -0.64 % | $ 14.3 B | ||
|
Invitae Corporation
NVTA
|
-93.18 | - | - | $ 21.2 M | ||
|
Mettler-Toledo International
MTD
|
35.8 | $ 1 262.91 | 0.24 % | $ 26 B | ||
|
Myriad Genetics
MYGN
|
-105.22 | $ 4.72 | -0.53 % | $ 437 M | ||
|
ENDRA Life Sciences
NDRA
|
-185.74 | $ 4.6 | -1.92 % | $ 3.62 M | ||
|
NeoGenomics
NEO
|
-9.11 | $ 8.0 | - | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
-51.22 | $ 9.47 | 0.64 % | $ 2.05 B | ||
|
National Research Corporation
NRC
|
161.47 | $ 17.38 | 1.25 % | $ 389 M |